Rousseau C.,ICO Gauducheau |
Rousseau C.,French Institute of Health and Medical Research |
Lacombe M.,ICO Gauducheau |
Pallardy A.,French Institute of Health and Medical Research |
And 10 more authors.
Medecine Nucleaire | Year: 2012
Behavioral heterogeneity within a given patient cohort has been a major challenge in clinical practice and is probably most prominently observed in the field of oncology. This has been the prime impetus of the cutting-edge preclinical and clinical research studies over recent times, many of which seek to further stratify patients based on patients' genetic, proteomic, and metabolic profile, in order to select the appropriate therapy according to an individual's best-fit. Molecular imaging of breast cancer can potentially be used for breast cancer staging, restaging, response evaluation and guiding therapies. This review focuses on PET imaging which can provide sensitive serial non-invasive information of tumor characteristics. Increasingly, more breast cancer specific targets are imaged such as estrogen receptor (ER) and growth factors. Although molecular imaging of breast cancer is still not commonly used in daily clinical practice, its application portfolio is expanding rapidly. © 2012 Elsevier Masson SAS. Source